Item 7.01 Regulation FD Disclosure.

On January 13, 2022, Adagio Therapeutics, Inc. (the "Company") intends to make a presentation at the J.P. Morgan Healthcare Conference, a copy of which can be found on the Company's website at https://investors.adagiotx.com/news-events/events-presentations and is incorporated herein by reference.

The information in this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On January 12, 2022, the Company issued a press release entitled "Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron." The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.



(d)  Exhibits



Exhibit
  No.                                    Description

99.1          Press release, dated January 12, 2022.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses